CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and a tumor marker for anaplastic large cell lymphoma. From Wikipedia
The novel CAR-T therapy demonstrates over 55% complete remission in ongoing Phase II, building on Phase I's 100% response rate and durable remissions.
